BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-604@pharmaconomics
DTSTAMP:20260707T034113Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:PVLA AdCom — QTORIN™ rapamycin (estimated date)
DESCRIPTION:An FDA advisory committee reviews QTORIN™ rapamycin for cutaneous venous malformations around ~ Jun 30\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/604
URL:https://www.pharmaconomics.com/e/604
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PVLA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR